Current Collaborations

AmpliPhi is receiving initial funding support from Cystic Fibrosis Foundation Therapeutics, Inc., a nonprofit affiliate of the Cystic Fibrosis Foundation. The funding will support development of BioPhage-PR. The company plans to evaluate the use of BioPhage-PR in aerosolised form for the treatment of lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.